Loading...
  •  

ThermoGenesis AXP® II and PXP® Systems Now Registered and Available in Thailand

ThermoGenesis AXP® II and PXP® Systems Now Registered and Available in Thailand

April 10, 2019

RANCHO CORDOVA, Calif., April 10, 2019 /PRNewswire/ -- ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing and autologous cell therapies for regenerative medicine, today announced that its AXP® II System  for cord blood processing and PXP® System for point-of-care harvesting of highly enriched mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) from bone marrow, while significantly reducing red blood cells (RBCs), are now registered and available for sale in Thailand. Both systems are part of an advanced and clinically differentiated portfolio of cellular processing solutions aimed at supporting the development of cell-based therapeutics, including the emerging CAR-T market.

"Expanding our footprint into Southeast Asia is a logical next step, especially  as research and development activities in the field of cell therapy are robust across Asia," said Haihong Zhu, ThermoGenesis' President. "We look forward to supporting the needs of hospitals, clinics and GMP laboratory customers with our state-of-the-art and cost-effective cell-based therapy tools."

About the AXP® II System
The AXP® II System is a proprietary, automated system for the isolation, collection and storage of hematopoietic stem cell concentrates from cord blood.
Its functionality:

  • automates the volume reduction process,
  • provides consistent buffy coat concentration volumes,
  • ensures high recoveries of mononuclear cells in a targeted volume, and
  • allows for simultaneously processing of multiple cord blood units in one centrifuge.

The AXP® II System includes the AXP II Device, AXP II Docking Station, AXP Processing Bag Set, XpressTRAK® software and accessories.

About the PXP® System
The PXP® laboratory equipment allows for the rapid, automated processing of autologous bone marrow-derived stem cells at the point of care, such as in surgical centers and clinics.
It affords:

  • consistently high recovery of MSCs and HSCs
  • greater than 99% RBC depletion
  • automation of the volume reduction process,
  • the simultaneous processing of multiple bone marrow units, and
  • the processing of bone marrow without cell separation media or a sedimentation agent.

­­­­About ThermoGenesis
ThermoGenesis develops, commercializes and markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company has developed an automated, functionally-closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market. For additional information, please visit: www.thermogenesis.com.

About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. is a market leader in cell processing technologies and autologous cell therapies for regenerative medicine. For more information, visit: www.cescatherapeutics.com.

Company Contact:
Wendy Samford
916-858-5191
ir@thermogenesis.com

Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com

Cision View original content:http://www.prnewswire.com/news-releases/thermogenesis-axp-ii-and-pxp-systems-now-registered-and-available-in-thailand-300829515.html

SOURCE Cesca Therapeutics Inc.